The different path of T790M-positive EGFR-mutant lung cancer.
作者信息
Yoon Shinkyo, Choi Chang Min, Lee Jae Cheol
机构信息
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Songpa-gu, Seoul, Korea.
Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Songpa-gu, Seoul, Korea.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S47. doi: 10.21037/atm.2018.10.01.
Abstract
摘要
相似文献
1
The different path of T790M-positive EGFR-mutant lung cancer.T790M阳性表皮生长因子受体（EGFR）突变型肺癌的不同路径
Ann Transl Med. 2018 Nov;6(Suppl 1):S47. doi: 10.21037/atm.2018.10.01.
2
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.EGFR突变型肺癌中散发性原发性EGFR T790M突变的临床可能性
Clin Lung Cancer. 2015 Jan;16(1):46-50. doi: 10.1016/j.cllc.2014.09.002. Epub 2014 Sep 28.
3
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.TAE226，一种双苯胺嘧啶化合物，可抑制包括T790M突变体在内的表皮生长因子受体（EGFR）突变激酶，对EGFR突变的非小细胞肺癌细胞显示出抗肿瘤作用。
PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015.
4
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.EGFR-TKI 获得性耐药后个体 EGFR 突变型非小细胞肺癌患者中 T790M 的时空异质性。
J Thorac Oncol. 2015 Nov;10(11):1553-9. doi: 10.1097/JTO.0000000000000647.
5
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.T790M突变在EGFR突变的晚期肺腺癌患者EGFR-TKI再挑战治疗中的作用。
Oncotarget. 2017 Jan 17;8(3):4994-5002. doi: 10.18632/oncotarget.14007.
6
Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.发现一种强效且突变选择性的 EGFR 抑制剂，可克服肺癌中 T790M 介导的耐药性。
Target Oncol. 2018 Jun;13(3):389-398. doi: 10.1007/s11523-018-0568-z.
7
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.高敏非侵入性检测非小细胞肺癌中表皮生长因子受体 T790M 突变。
Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.
8
Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.基于星形孢菌素骨架，利用模拟敏感激酶技术合理发现肺癌中表皮生长因子受体（EGFR）T790M守门人突变型的野生型保留型可逆抑制剂。
J Mol Recognit. 2017 Apr;30(4). doi: 10.1002/jmr.2590. Epub 2016 Nov 28.
9
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.临床因素预测 EGFR 突变型非小细胞肺癌再次活检中 T790M 突变的检测。
Clin Lung Cancer. 2018 Mar;19(2):e247-e252. doi: 10.1016/j.cllc.2017.07.002. Epub 2017 Aug 10.
10
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.针对 EGFR 酪氨酸激酶抑制剂耐药的非小细胞肺癌细胞系中 EGFR T790M 突变的 siRNA 的作用及与各种药物联合应用。
Biochem Biophys Res Commun. 2013 Feb 15;431(3):623-9. doi: 10.1016/j.bbrc.2012.12.070. Epub 2012 Dec 22.
本文引用的文献
1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
2
Understanding and targeting resistance mechanisms in NSCLC.了解和靶向非小细胞肺癌的耐药机制。
Nat Rev Cancer. 2017 Oct 25;17(11):637-658. doi: 10.1038/nrc.2017.84.
3
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者中 T790M 突变对疾病特征和治疗反应的临床意义
Clin Lung Cancer. 2018 Jan;19(1):e19-e28. doi: 10.1016/j.cllc.2017.06.004. Epub 2017 Jun 20.
4
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.靶向“守门员”：奥希替尼治疗 EGFR T790M 突变阳性非小细胞肺癌。
Clin Cancer Res. 2017 Feb 1;23(3):618-622. doi: 10.1158/1078-0432.CCR-15-2815. Epub 2016 Nov 7.
5
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma.肺腺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药机制及克服耐药的策略
Tuberc Respir Dis (Seoul). 2016 Oct;79(4):248-256. doi: 10.4046/trd.2016.79.4.248. Epub 2016 Oct 5.
6
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.胰岛素样生长因子1受体（IGF1R）通路的激活可能介导晚期非小细胞肺癌对突变选择性第三代表皮生长因子受体酪氨酸激酶抑制剂产生获得性耐药。
Oncotarget. 2016 Apr 19;7(16):22005-15. doi: 10.18632/oncotarget.8013.
7
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.一线使用表皮生长因子受体（EGFR）酪氨酸激酶抑制剂的EGFR突变型肺癌患者化疗敏感性降低
Lung Cancer. 2014 Nov;86(2):219-24. doi: 10.1016/j.lungcan.2014.09.008. Epub 2014 Sep 18.
8
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.T790M 突变与晚期 NSCLC 患者在 EGFR-TKI 治疗进展后更好的疗效相关。
Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.
9
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.表皮生长因子受体酪氨酸激酶抑制剂治疗失败后的非小细胞肺癌治疗。
Cancer Res Treat. 2013 Jun;45(2):79-85. doi: 10.4143/crt.2013.45.2.79. Epub 2013 Jun 30.
10
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.基于进化癌症建模的 EGFR 突变型非小细胞肺癌给药优化。
Sci Transl Med. 2011 Jul 6;3(90):90ra59. doi: 10.1126/scitranslmed.3002356.
Zotero 插件